If you or someone in your family has experienced a serious side effect to a health product, you are encouraged to report the experience to your health care professional (e.g. physician, pharmacist). You could also complete a copy of the side effect reporting form or report your side effect to FDA.
Panadeine Side Effects Reported to FDA
Panadeine Side Effect Report#7655041-8 Haemothorax, Gastrointestinal Haemorrhage, Cardiac Failure, Cardiac Function Disturbance Postoperative, Gastric Ulcer Perforation
This is a report of a 82-year-old female patient (weight: NA) from Norway, suffering from the following health symptoms/conditions: NA, who was treated with Panadeine Forte (paracetamol, Codeine Phosphate) (dosage: NA, start time:
Jan 01, 2011), combined with:
and developed a serious reaction and side effect(s): Haemothorax, Gastrointestinal Haemorrhage, Cardiac Failure, Cardiac Function Disturbance Postoperative, Gastric Ulcer Perforation after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Panadeine Forte (paracetamol, Codeine Phosphate) treatment in female patients, resulting in Haemothorax side effect.
Panadeine Side Effect Report#7593514-7 Suicidal Ideation, Self Injurious Behaviour
This report suggests a potential Panadeine ForteSuicidal Ideation side effect(s) that can have serious consequences. A 23-year-old female patient (weight: NA) from Australia was diagnosed with the following symptoms/conditions: NA and used Panadeine Forte (dosage: NA) starting NS. After starting Panadeine Forte the patient began experiencing various side effects, including: Suicidal Ideation, Self Injurious BehaviourAdditional drugs used concurrently:
Diazepam (Dose Reduced)
Although Panadeine Forte demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as Suicidal Ideation, may still occur.
Panadeine Side Effect Report#7557730-2 Atrial Fibrillation, Palpitations, Hypertension, Embolic Stroke
This Atrial Fibrillation problem was reported by a physician from Australia. A 58-year-old male patient (weight: NA) was diagnosed with the following symptoms/conditions: pain,arthritis,hypertension. On
Jan 01, 1981 this consumer started treatment with Panadeine Forte (dosage: Two To Three Doses As Needed). The following drugs were being taken at the same time:
Celebrex (200 Mg, 1x/day)
Perindopril Erbumine (4 Mg, 1x/day)
Tramadol Hcl (200 Mg, 2x/day)
Capadex (One To Two Doses As Needed)
When using Panadeine Forte, the patient experienced the following unwanted symptoms/side effects: Atrial Fibrillation, Palpitations, Hypertension, Embolic StrokeAlthough all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as Atrial Fibrillation, may become evident only after a product is in use by the general population.
Panadeine Side Effect Report#7289934-0 Cholecystitis, Helicobacter Infection, Peptic Ulcer Haemorrhage
This Cholecystitis side effect was reported by a consumer or non-health professional from United Kingdom. A 64-year-old male patient (weight:NA) experienced the following symptoms/conditions: NA.The patient was prescribed Panadeine Co (panadeine Co) (drug dosage: NA), which was initiated on NS. Concurrently used drugs:
Sertraline Hydrochloride (50 Mg;po;qd)
.After starting to take Panadeine Co (panadeine Co) the consumer reported adverse symptoms, such as: Cholecystitis, Helicobacter Infection, Peptic Ulcer HaemorrhageThese side effects may potentially be related to Panadeine Co (panadeine Co). The patient was hospitalized.
This is a report of a 37-year-old female patient (weight: NA) from Australia, suffering from the following health symptoms/conditions: NA, who was treated with Panadeine (dosage: 2 Doses/day, start time:
Mar 14, 2007), combined with:
Famvir (750 Mg/day)
and developed a serious reaction and side effect(s): Abdominal Pain, Anxiety, Dizziness, Hallucination, Insomnia, Nausea after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Panadeine treatment in female patients, resulting in Abdominal Pain side effect.
The appearance of Panadeine on this list does not mean that FDA has concluded that the drug has the listed risk. It means that FDA has identified a potential safety issue, but it does not mean that FDA has found a causal relationship between the drug and the listed risk.
It is really important to keep track of your health symptoms, right from the time you start a new medicine. You can do it any way you prefer: in a notebook, in a computer file or using our online tool. You should also note down any other medicines you are taking at the same time, because there could be an interaction between these medicines.
Why Your Notes are Important
Your notes could be helpful in several ways:
You can use them to remind you of details that may alert your health care professional(s) to a problem
You will have a record to refer to in the future, in case you are ever prescribed the same medicine again
You can use the following log form to write down important information, like the date and time you experienced a side effect and your symptoms, how strong the symptoms were, and any other medicines you were using.
Medicine Name and Dosage:
Date & Time
Other Medicine(s) or Treatment(s)
Scale: 1 = very mild to 10 = very bad
Side effects reports are analyzed to discover potential health product safety signals. Some important reactions may take an extremely long time to develop or occur infrequently. Continued monitoring of adverse reactions is thus essential to maintain a comprehensive safety and effectiveness profile of health products.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Panadeine reports list potential signals of serious risks and new safety information that were identified using the FDA Adverse Event Reporting System (FAERS).
FAERS is a database that contains information on adverse event and medication errors reports submitted to FDA by healthcare professionals (such as physicians, pharmacists, nurses and others), consumers (such as patients, family members, layers and others) and manufacturers.